Metabolic abnormalities associated with second generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring

International Clinical Psychopharmacology

Volumn 21, Issue SUPPL. 2, 2006, Pages

  De Hert, Marc ^a   Van Eyck, Dominique ^a   De Nayer, Andre ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Hopital Sainte Therese   (Belgium)

Author keywords

Diabetes; Metabolic side effects; Physical health; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

COHORT ANALYSIS; DIABETES MELLITUS; HIGH RISK PATIENT; HUMAN; METABOLIC DISORDER; MONITORING; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; SCREENING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; DRUG MONITORING; HUMANS; METABOLIC DISEASES; METABOLIC SYNDROME X; PRACTICE GUIDELINES;

EID: 33646679115     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000201496.23259.85     Document Type: Review

References (41)

1. Alberti G (2005). Introduction to the metabolic syndrome. Eur Heart J Suppl 7:3-5.
2. American Diabetes Association (2002). Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 (Suppl 1):33-50.
3. American Diabetes Association (2004a). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 27:S5-S10.
4. American Diabetes Association (2004b). Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27:596-601.
5. Caro JJ, Ward A, Levinton C, Robinson K (2002). The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63:1135-1139.
6. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, et al. (2004). Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patient with schizophrenia. J Clin Psychiatry 65:4-18.
7. Citrome LL, Jaffe AB (2003). Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 37:1849-1857.
8. Clark C, Burge MR (2003). Diabetes mellitus associated with atypical antipsychotic medications. Diabetes Technol Ther 5:669-683.
9. Cleeman JI (2001). Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 285:2486-2497.
10. De Hert M, Van Eyck D, Hanssens L, Peuskens H, Thys E, Wampers M, (2005). Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry Aug 31 [Epub ahead of print].
11. De Hert M, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. (2006). Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schiz Res (in press).
12. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J, on Behalf of the Consensus Group (2005). Belgian consensus on metabolic problems associated with second generation antipsychotics. Int J Psychiatry Clin Pract 9:130-137.
13. Dynes JB (1969). Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst 30:341-344.
14. Expert Group (2004). 'Schizophrenia and Diabetes 2003'. Expert Consensus Meeting, Dublin, 3-4 October: consensus summary. Br J Psychiatry 47 (Suppl):S112-S114.
15. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA (2002). Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63:920-930.
16. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004). Definition of Metabolic Syndrome: report of the National Heart, Lung, and Blood Institute. American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109:433-438.
17. Haffner SM, Miettinen H, Stern MP (1997). The homeostasis model in the San Antonio Heart Study. Diabetes Care 20:1087-1092.
18. Haupt DW, Newcomer JW (2001). Hyperglycaemia and antipsychotic medications. J Clin Psychiatry 62 (Suppl 27):15-26.
19. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O (2002). Glucose intolerance with atypical antipsychotics. Drug Saf 25:1107-1116.
20. Henderson DC (2002). Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16:77-89.
21. Henderson D (2003). Medical Illness and Schizophrenia. In: Meyer J, Nasrallah H (editors). Title. Washington, DC: American Psy. Publishing.
22. International Diabetes Federation (2005). The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, International Diabetes Federation http://www.idf.org/home/index.cfm?unode=1120071E-AACE-41D2-9FAO- BAB6E25BA072.
23. Jin H, Meyer JM, Jeste DV (2004). Atypical antipsychotics and glucose deregulation: a systematic review. Schizophr Res 71:195-212.
24. Koller E, Schneider B, Bennett K, Dubitsky G (2001). Clozapine-associated diabetes. Am J Med 111:716-723.
25. Koller EA, Cross JT, Doraiswamy PM, Schneider BS (2003). Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 23:735-744.
26. Koller EA, Doraiswamy PM (2002). Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852.
27. Koller EA, Weber J, Doraiswamy PM, Schneider BS (2004). A survey of reports of quetiapine-associated hyperglycaemia and diabetes mellitus. J Clin Psychiatry 65:857-863.
28. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. (2002). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:243.
29. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334-1349.
30. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32.
31. Melkersson K, Dahl ML (2004). Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701-723.
32. Meyer JM, Koro CE (2004). The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1-17.
33. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL (1996). Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68-73.
34. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1):1-93.
35. Rietzschel E, De Buyzere M, De Bacquer D, Langlois M, Bekaert S, De Backer G, et al. (2005). Metabolic syndrome, a map of the cardiovascular damage. Results from the asklepios study in 2528 apparently healthy 35-55-year-old subjects. Abstracts Conference European Society of Cardiology. Eur Heart J 26:110.
36. Scheen A, De Hert M (2004). Risque de diabete sucre sous antipsychotiques atyptiques. Méd Hyg 507:1591-1596.
37. Scheen AJ, De Hert D (2005). Drug-induced diabetes mellitus: the example of atypical antipsychotics. Rev Med Liege 60:455-60.
38. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566.
39. Subramaniam M, Chong SA, Pek E (2003). Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48:345-347.
40. Unwin N, Shaw J, Zimmet P, Alberti KG (2002). Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:708-723.
41. World Health Organization (1999). Part 1: Diagnosis and classification of diabetes mellitus. Definition diagnosis and classification of diabetes mellitus and its complications Report of a WHO Consultation. Geneva, Switzerland: WHO.